122 related articles for article (PubMed ID: 32513785)
21. Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.
Fabian CJ; Kimler BF; Zalles CM; Phillips TA; Metheny T; Petroff BK; Havighurst TC; Kim K; Bailey HH; Heckman-Stoddard BM
Cancer Prev Res (Phila); 2015 Dec; 8(12):1146-55. PubMed ID: 26391916
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
[TBL] [Abstract][Full Text] [Related]
23. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
[TBL] [Abstract][Full Text] [Related]
24. A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.
Aristarco V; Serrano D; Gandini S; Johansson H; Macis D; Guerrieri-Gonzaga A; Lazzeroni M; Feroce I; Pruneri G; Pagani G; Toesca A; Caldarella P; DeCensi A; Bonanni B
Cancer Prev Res (Phila); 2016 May; 9(5):349-56. PubMed ID: 26928670
[TBL] [Abstract][Full Text] [Related]
25. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease.
Horne HN; Sherman ME; Pfeiffer RM; Figueroa JD; Khodr ZG; Falk RT; Pollak M; Patel DA; Palakal MM; Linville L; Papathomas D; Geller B; Vacek PM; Weaver DL; Chicoine R; Shepherd J; Mahmoudzadeh AP; Wang J; Fan B; Malkov S; Herschorn S; Hewitt SM; Brinton LA; Gierach GL
Breast Cancer Res; 2016 Feb; 18(1):24. PubMed ID: 26893016
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes.
Goodwin PJ; Ennis M; Pritchard KI; Trudeau ME; Koo J; Hartwick W; Hoffma B; Hood N
Breast Cancer Res Treat; 2002 Jul; 74(1):65-76. PubMed ID: 12150454
[TBL] [Abstract][Full Text] [Related]
27. Chemoprevention for high-risk women: tamoxifen and beyond.
Fabian CJ; Kimler BF
Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
[TBL] [Abstract][Full Text] [Related]
28. Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women.
Schmitz KH; Ahmed RL; Yee D
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1597-604. PubMed ID: 12496050
[TBL] [Abstract][Full Text] [Related]
29. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
[TBL] [Abstract][Full Text] [Related]
30. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women.
Bonanni B; Johansson H; Gandini S; Guerrieri-Gonzaga A; Torrisi R; Sandri MT; Cazzaniga M; Mora S; Robertson C; Lien EA; Decensi A
Breast Cancer Res Treat; 2001 Sep; 69(1):21-7. PubMed ID: 11759825
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
[TBL] [Abstract][Full Text] [Related]
32. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
[TBL] [Abstract][Full Text] [Related]
33. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Vinayak S; Schwartz EJ; Jensen K; Lipson J; Alli E; McPherson L; Fernandez AM; Sharma VB; Staton A; Mills MA; Schackmann EA; Telli ML; Kardashian A; Ford JM; Kurian AW
Breast Cancer Res Treat; 2013 Nov; 142(2):389-98. PubMed ID: 24166281
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.
Levitt RJ; Buckley J; Blouin MJ; Schaub B; Triche TJ; Pollak M
Biochem Biophys Res Commun; 2004 Apr; 316(2):421-8. PubMed ID: 15020235
[TBL] [Abstract][Full Text] [Related]
35. Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.
Schairer C; Hill D; Sturgeon SR; Fears T; Pollak M; Mies C; Ziegler RG; Hoover RN; Sherman ME
Int J Cancer; 2004 Feb; 108(5):773-9. PubMed ID: 14696106
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
37. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.
Akkoc Mustafayev FN; Liu DD; Gutierrez AM; Lewis JE; Ibrahim NK; Valero V; Booser DJ; Litton JK; Koenig K; Yu D; Sneige N; Arun BK
Eur J Breast Health; 2023 Oct; 19(4):267-273. PubMed ID: 37795002
[TBL] [Abstract][Full Text] [Related]
38. IGF1 and risk of additional breast cancer in the WHEL study.
Al-Delaimy WK; Flatt SW; Natarajan L; Laughlin GA; Rock CL; Gold EB; Caan BJ; Parker BA; Pierce JP
Endocr Relat Cancer; 2011 Apr; 18(2):235-44. PubMed ID: 21263044
[TBL] [Abstract][Full Text] [Related]
39. Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
Monson KR; Goldberg M; Wu HC; Santella RM; Chung WK; Terry MB
Breast Cancer Res; 2020 Oct; 22(1):109. PubMed ID: 33092613
[TBL] [Abstract][Full Text] [Related]
40. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.
Kaulsay KK; Ng EH; Ji CY; Ho GH; Aw TC; Lee KO
Eur J Endocrinol; 1999 Feb; 140(2):164-8. PubMed ID: 10069662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
